Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Diffuse Large B-cell Lymphoma, Indolent Non-Hodgkin's Lymphoma
Conditions
Keywords
GS-US-339-0103, SYK inhibitor, PI3K inhibitor, GS-9973, GS 9973, GS-1101, GS 1101, Cal-101, Cal 101, idelalisib, leukemia, lymphoma, CLL, MCL, DLBCL, iNHL, FL, MZL, LPL, SLL, WM, Waldenström's macroglobulinemia
Brief summary
This study will evaluate the efficacy of the combination entospletinib and idelalisib in participants with relapsed or refractory hematologic malignancies. Participants will be enrolled who have one of the following hematological tumor types: chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), or indolent non-Hodgkin lymphomas (iNHL; including follicular lymphoma (FL) and lymphoplasmacytoid lymphoma/Waldenström macroglobulinemia \[LPL/WM\], small lymphocytic lymphoma \[SLL\], or marginal zone lymphoma \[MZL\]).
Interventions
DRUGEntospletinib
Entospletinib tablets administered orally twice daily
DRUGIdelalisib
Idelalisib tablets administered orally twice daily
Sponsors
Gilead Sciences
Study design
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Key Inclusion Criteria: * Diagnosis of B-cell indolent non-Hodgkin lymphoma (iNHL),diffuse large B-cell lymphoma (DLBCL),mantle cell lymphoma (MCL), or chronic lymphocytic leukemia (CLL) as documented by medical records and with histology based on criteria established by the World Health Organization * For institutions that have Phase 3 or Phase 4 protocols studying idelalisib (Zydelig®; GS-1101); individuals with malignancies being studied in these protocols must have failed screening and be registered as a screen failure in the respective idelalisib protocol * Prior treatment for lymphoid malignancy * Presence of radiographically measurable lymphadenopathy or extranodal lymphoid malignancy * Discontinuation of all therapy for the treatment of cancer ≥ 3 weeks before the start of study drug * All acute toxic effects of any prior antitumor therapy resolved to Grade ≤ 1 before the start of study drug * Karnofsky performance status of ≥ 60 * Life expectancy of at least 3 months Key
Exclusion criteria
* Known histological transformation from iNHL or CLL to an aggressive form of NHL (ie, Richter transformation) * Known active central nervous system or leptomeningeal lymphoma * Presence of known intermediate- or high-grade myelodysplastic syndrome * Current therapy with agents that reduce gastric acidity, including but not limited to antacids, H2 inhibitors, and proton pump inhibitors * Evidence of ongoing systemic bacterial, fungal, or viral infection at the time of start of study drug * Ongoing liver injury * Ongoing or recent hepatic encephalopathy * Ongoing drug-induced pneumonitis * Ongoing inflammatory bowel disease * Ongoing alcohol or drug addiction * Pregnancy or breastfeeding * History of prior allogeneic bone marrow progenitor cell or solid organ transplantation * Ongoing immunosuppressive therapy * Concurrent participation in an investigational drug trial with therapeutic intent Note: Other protocol defined Inclusion/
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate (ORR) | Start of treatment to end of treatment (Up to 18 months) | ORR assessed by the Independent Review Committee (IRC), was based on the International Working Group Revised Response Criteria (Cheson, 2012) and investigator's response, defined as the percentage of participants achieving a complete response (CR) or partial response (PR) (or very good partial response \[VGPR\] or minor response \[MR\] for participants with LPL/WM). CR was defined as the complete resolution of all disease-related radiological abnormalities and the disappearance of all signs and symptoms related to the disease. PR was defined as a ≥ 50% reduction in the sum of the products of the longest perpendicular diameters of all index lesions, with no new lesions. VGPR and MR were defined as ≥ 90% and ≥ 25% but \< 50% decrease from baseline in serum monoclonal immunoglobulin M (IgM) concentration by serum protein electrophoresis (SPEP) respectively. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | First dose date up to the last dose date plus 30 days (maximum: 18 months) | A treatment-emergent laboratory (Hematology, Serum Chemistry and Urinalysis) abnormality was defined as an abnormality that, compared to baseline, worsens by ≥ 1 grade in the period from the first dose of study drug. Safety as assessed by grading of laboratory values and AEs according to the National Cancer Institutes' Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03. Grade 0 = none, Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = life threatening or disabling. If baseline data are missing, then any graded abnormality (i.e., an abnormality that is Grade ≥ 1 in severity) will be considered treatment-emergent. The percentage of participants in each worst postbaseline grade is reported. |
| Maximum Tolerated Dose Level | First dose (entospelinib + idelalisib) date up to 6 months | Maximum tolerated dose (MTD) is defined as the highest dose level that was consistently well tolerated without dose limiting toxicity (DLT) for the majority of participants time on treatment (ie,\> 50%) as determined by the investigator for each participant. DLTs are defined as Grade 4 hematological toxicities persisting for ≥ 14 days or Grade ≥ 3 toxicities of other types. |
| Percentage of Participants Experiencing Treatment-Emergent Adverse Events | First dose date up to the last dose date plus 30 days (maximum duration: 19 months) | A treatment-emergent Adverse Event (AE) was defined as any AE with an onset date of on or after the study drug start date and no later than 30 days after permanent discontinuation of study drugs or an AE leading to premature discontinuation of study drug. An AE is any untoward medical occurrence in a clinical investigation where participants administered a medicinal product, and which does not necessarily have a causal relationship with this treatment. |
| Duration of Response (DOR) | Start of treatment to end of treatment (Up to 18 months) | DOR was defined as the interval from the first-time response (CR or PR \[or VGPR or MR for participants with LPL/WM\]) is achieved to the earlier of the first documentation of definitive disease progression or death from any cause.CR was defined as the complete resolution of all disease-related radiological abnormalities and the disappearance of all signs and symptoms related to the disease. PR was defined as a ≥ 50% reduction in the sum of the products of the longest perpendicular diameters of all index lesions, with no new lesions. VGPR and MR were defined as ≥ 90% and ≥ 25% but \< 50% decrease from baseline in serum monoclonal IgM concentration by SPEP respectively. |
| Time to Response (TTR) | Start of treatment to end of treatment (Up to 18 months) | TTR was defined as the interval from the first dose of entospletinib/idelalisib to the time response (CR or PR \[or VGPR or MR for participants with LPL/WM\]) is first achieved. CR was defined as the complete resolution of all disease-related radiological abnormalities and the disappearance of all signs and symptoms related to the disease. PR was defined as a ≥ 50% reduction in the sum of the products of the longest perpendicular diameters of all index lesions, with no new lesions. VGPR and MR were defined as ≥ 90% and ≥ 25% but \< 50% decrease from baseline in serum monoclonal IgM concentration by SPEP respectively. |
| Progression-free Survival (PFS) | Start of treatment to end of treatment (Up to 18 months) | PFS was defined as the interval from the first dose of study drug to the earlier of the first documentation of definitive disease progression or death from any cause. |
Countries
United States
Participant flow
Recruitment details
Participants were enrolled at study sites in the United States. The first participant was screened on 20 June 2013. The last study visit occurred on 22 December 2016.
Pre-assignment details
85 participants were screened.
Participants by arm
| Arm | Count |
|---|---|
| Entospletinib + Idelalisib CLL Participants with a documented diagnosis of chronic lymphocytic leukemia (CLL) were included in this arm. Participants were administered 4 dose combinations of entospletinib plus idelalisib tablets orally twice daily under fasted conditions (400 mg/100 mg for 2 weeks, if no dose limiting toxicity (DLT) occurred, increased dose to 600 mg/100 mg for 2 weeks, if no DLT occurred, increased dose to 800 mg/100 mg for 4 weeks, if no DLT occurred, increased dose to 800 mg/150 mg) for up to 6 months. After discontinuation of combination therapy and a washout period of 14-28 days, participants could continue to receive entospletinib 400 mg monotherapy for up to 18 months. | 35 |
| Entospletinib + Idelalisib iNHL: FL Participants with a documented diagnosis of indolent non-Hodgkin lymphoma (iNHL) with follicular lymphoma (FL) were included in this arm. Participants were administered 4 dose combinations of entospletinib plus idelalisib tablets orally twice daily under fasted conditions (400 mg/100 mg for 2 weeks, if no dose limiting toxicity (DLT) occurred, increased dose to 600 mg/100 mg for 2 weeks, if no DLT occurred, increased dose to 800 mg/100 mg for 4 weeks, if no DLT occurred increased dose to 800 mg/150 mg) for up to 6 months. After discontinuation of combination therapy and a washout period of 14-28 days, participants could continue to receive entospletinib 400 mg monotherapy for up to 18 months | 14 |
| Entospletinib + Idelalisib DLBCL Participants with a documented diagnosis of diffuse large B-cell lymphoma (DLBCL) were included in this arm. Participants were administered 4 dose combinations of entospletinib plus idelalisib tablets orally twice daily under fasted conditions (400 mg/100 mg for 2 weeks, if no dose limiting toxicity (DLT) occurred ,increased dose to 600 mg/100 mg for 2 weeks, if no DLT occurred, increased dose to 800 mg/100 mg for 4 weeks, if no DLT occurred, increased dose to 800 mg/150 mg) for up to 6 months. After discontinuation of combination therapy and a washout period of 14-28 days, participants could continue to receive entospletinib 400 mg monotherapy for up to 18 months. | 6 |
| Entospletinib + Idelalisib MCL Participants with a documented diagnosis of mantle cell lymphoma (MCL) were included in this arm. Participants were administered 4 dose combinations of entospletinib plus idelalisib tablets orally twice daily under fasted conditions (400 mg/100 mg for 2 weeks, if no dose limiting toxicity (DLT) occurred, increased dose to 600 mg/100 mg for 2 weeks, if no DLT occurred, increased dose to 800 mg/100 mg for 4 weeks, if no DLT occurred, increased dose to 800 mg/150 mg) for up to 6 months. After discontinuation of combination therapy and a washout period of 14-28 days, participants could continue to receive entospletinib 400 mg monotherapy for up to 18 months. | 3 |
| Entospletinib + Idelalisib iNHL: Others Participants with a documented diagnosis of iNHL with other subtypes lymphoplasmacytic lymphoma (LPL)/Waldenstrom macroglobulinemia (WM), small lymphocytic lymphoma (SLL) and marginal zone lymphoma (MZL) were included in this arm. Participants were administered 4 dose combinations of entospletinib plus idelalisib tablets orally twice daily under fasted conditions (400 mg/100 mg for 2 weeks, if no dose limiting toxicity (DLT) increased to 600 mg/100 mg for 2 weeks, if no DLT increased to 800 mg/100 mg for 4 weeks, if no DLT increased to 800 mg/150 mg) for up to 6 months. After discontinuation of combination therapy and a washout period of 14-28 days, participants could continue to receive entospletinib 400 mg monotherapy for up to 18 months. | 8 |
| Total | 66 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 |
|---|---|---|---|---|---|---|
| Overall Study | Adverse Event | 4 | 2 | 2 | 1 | 3 |
| Overall Study | Death | 2 | 0 | 0 | 0 | 1 |
| Overall Study | Initiated New Therapy | 9 | 0 | 0 | 0 | 2 |
| Overall Study | Lost to Follow-up | 0 | 1 | 0 | 0 | 0 |
| Overall Study | Physician Decision | 5 | 4 | 1 | 0 | 1 |
| Overall Study | Progressive Disease | 7 | 7 | 3 | 2 | 0 |
| Overall Study | Protocol Criteria for Withdrawal | 1 | 0 | 0 | 0 | 0 |
| Overall Study | Withdrawal by Subject | 7 | 0 | 0 | 0 | 1 |
Baseline characteristics
| Characteristic | Entospletinib + Idelalisib iNHL: FL | Total | Entospletinib + Idelalisib CLL | Entospletinib + Idelalisib iNHL: Others | Entospletinib + Idelalisib MCL | Entospletinib + Idelalisib DLBCL |
|---|---|---|---|---|---|---|
| Age, Continuous | 64 years STANDARD_DEVIATION 13.4 | 67 years STANDARD_DEVIATION 12.7 | 68 years STANDARD_DEVIATION 12.9 | 69 years STANDARD_DEVIATION 8.9 | 62 years STANDARD_DEVIATION 10.8 | 69 years STANDARD_DEVIATION 17.4 |
| Karnofsky Performance Status 100 | 2 Participants | 8 Participants | 6 Participants | 0 Participants | 0 Participants | 0 Participants |
| Karnofsky Performance Status 40 | 0 Participants | 1 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants |
| Karnofsky Performance Status 50 | 0 Participants | 1 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants |
| Karnofsky Performance Status 60 | 0 Participants | 3 Participants | 2 Participants | 0 Participants | 1 Participants | 0 Participants |
| Karnofsky Performance Status 70 | 1 Participants | 4 Participants | 2 Participants | 0 Participants | 0 Participants | 1 Participants |
| Karnofsky Performance Status 80 | 7 Participants | 24 Participants | 9 Participants | 5 Participants | 1 Participants | 2 Participants |
| Karnofsky Performance Status 90 | 4 Participants | 25 Participants | 14 Participants | 3 Participants | 1 Participants | 3 Participants |
| Race/Ethnicity, Customized Ethnicity Hispanic or Latino | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Ethnicity Not Hispanic or Latino | 12 Participants | 64 Participants | 35 Participants | 8 Participants | 3 Participants | 6 Participants |
| Race/Ethnicity, Customized Ethnicity Not Permitted | 2 Participants | 2 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Race Asian | 0 Participants | 2 Participants | 2 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Race Black or African American | 1 Participants | 6 Participants | 5 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Race Native Hawaiian or Other Pacific Islander | 0 Participants | 1 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Race Not Reported | 1 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Race Other | 1 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Race White/Caucasian | 11 Participants | 55 Participants | 27 Participants | 8 Participants | 3 Participants | 6 Participants |
| Sex: Female, Male Female | 6 Participants | 31 Participants | 15 Participants | 5 Participants | 1 Participants | 4 Participants |
| Sex: Female, Male Male | 8 Participants | 35 Participants | 20 Participants | 3 Participants | 2 Participants | 2 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk |
|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 3 / 35 | 1 / 14 | 2 / 6 | 2 / 3 | 2 / 8 |
| other Total, other adverse events | 34 / 35 | 14 / 14 | 6 / 6 | 3 / 3 | 8 / 8 |
| serious Total, serious adverse events | 24 / 35 | 2 / 14 | 4 / 6 | 2 / 3 | 5 / 8 |
Outcome results
Primary
Objective Response Rate (ORR)
ORR assessed by the Independent Review Committee (IRC), was based on the International Working Group Revised Response Criteria (Cheson, 2012) and investigator's response, defined as the percentage of participants achieving a complete response (CR) or partial response (PR) (or very good partial response \[VGPR\] or minor response \[MR\] for participants with LPL/WM). CR was defined as the complete resolution of all disease-related radiological abnormalities and the disappearance of all signs and symptoms related to the disease. PR was defined as a ≥ 50% reduction in the sum of the products of the longest perpendicular diameters of all index lesions, with no new lesions. VGPR and MR were defined as ≥ 90% and ≥ 25% but \< 50% decrease from baseline in serum monoclonal immunoglobulin M (IgM) concentration by serum protein electrophoresis (SPEP) respectively.
Time frame: Start of treatment to end of treatment (Up to 18 months)
Population: The study was terminated due to safety measures. Complete data was not collected for any participant.
Secondary
Duration of Response (DOR)
DOR was defined as the interval from the first-time response (CR or PR \[or VGPR or MR for participants with LPL/WM\]) is achieved to the earlier of the first documentation of definitive disease progression or death from any cause.CR was defined as the complete resolution of all disease-related radiological abnormalities and the disappearance of all signs and symptoms related to the disease. PR was defined as a ≥ 50% reduction in the sum of the products of the longest perpendicular diameters of all index lesions, with no new lesions. VGPR and MR were defined as ≥ 90% and ≥ 25% but \< 50% decrease from baseline in serum monoclonal IgM concentration by SPEP respectively.
Time frame: Start of treatment to end of treatment (Up to 18 months)
Population: The study was terminated due to safety measures. Complete data was not collected for any participant.
Secondary
Maximum Tolerated Dose Level
Maximum tolerated dose (MTD) is defined as the highest dose level that was consistently well tolerated without dose limiting toxicity (DLT) for the majority of participants time on treatment (ie,\> 50%) as determined by the investigator for each participant. DLTs are defined as Grade 4 hematological toxicities persisting for ≥ 14 days or Grade ≥ 3 toxicities of other types.
Time frame: First dose (entospelinib + idelalisib) date up to 6 months
Population: The study was terminated due to safety measures. Complete data was not collected for any participant.
Secondary
Percentage of Participants Experiencing Treatment-Emergent Adverse Events
A treatment-emergent Adverse Event (AE) was defined as any AE with an onset date of on or after the study drug start date and no later than 30 days after permanent discontinuation of study drugs or an AE leading to premature discontinuation of study drug. An AE is any untoward medical occurrence in a clinical investigation where participants administered a medicinal product, and which does not necessarily have a causal relationship with this treatment.
Time frame: First dose date up to the last dose date plus 30 days (maximum duration: 19 months)
Population: The Safety Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Adverse Events | 100 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Adverse Events | 100 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Adverse Events | 100 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Adverse Events | 100 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Adverse Events | 100 percentage of participants |
Secondary
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities
A treatment-emergent laboratory (Hematology, Serum Chemistry and Urinalysis) abnormality was defined as an abnormality that, compared to baseline, worsens by ≥ 1 grade in the period from the first dose of study drug. Safety as assessed by grading of laboratory values and AEs according to the National Cancer Institutes' Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03. Grade 0 = none, Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = life threatening or disabling. If baseline data are missing, then any graded abnormality (i.e., an abnormality that is Grade ≥ 1 in severity) will be considered treatment-emergent. The percentage of participants in each worst postbaseline grade is reported.
Time frame: First dose date up to the last dose date plus 30 days (maximum: 18 months)
Population: Participants in the Safety Analysis Set were analyzed.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Lymphocyte Count Decreased (Grade 1) | 0 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Leukocytosis (Grade 1) | 0 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Lymphocyte Count Decreased (Grade 2) | 0 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Anemia (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypophosphatemia (Grade 3) | 5.7 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Alkaline Phosphatase (ALP) Increased (Grade 1) | 17.1 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypophosphatemia (Grade 1) | 0 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypophosphatemia (Grade 2) | 2.9 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | WBC Count Decreased (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | ALP Increased (Grade 3) | 0 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Anemia (Grade 3) | 5.7 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hyperglycemia (Grade 1) | 11.4 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Anemia (Grade 2) | 14.3 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypophosphatemia (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Lymphocyte Count Increased (Grade 3) | 28.6 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Lymphocyte Count Increased (Grade 2) | 8.6 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hyperglycemia (Grade 3) | 11.4 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypokalemia (Grade 1) | 20.0 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | WBC Count Decreased (Grade 3) | 5.7 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hyponatremia (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | ALT Increased (Grade 3) | 0 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Anemia (Grade 1) | 20.0 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypokalemia (Grade 2) | 0 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Aspartate Aminotransferase (AST)Increased(Grade 1) | 20.0 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | WBC Count Decreased (Grade 2) | 14.3 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypoalbuminemia (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hyponatremia (Grade 1) | 20.0 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Neutrophils Count Decreased (Grade 4) | 11.4 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hyperglycemia (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Lymphocyte Count Increased (Grade 1) | 0 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Alanine Aminotransferase (ALT) Increased (Grade 1) | 22.9 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Neutrophils Count Decreased (Grade 3) | 14.3 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypokalemia (Grade 3) | 0 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hyperglycemia (Grade 2) | 5.7 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Blood Bilirubin Increased (Grade 2) | 25.7 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Platelets Count Decreased (Grade 4) | 2.9 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Neutrophils Count Decreased (Grade 2) | 20.0 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypoalbuminemia (Grade 3) | 0 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | White Blood Cell Count Decreased (Grade 1) | 0 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Neutrophils Count Decreased (Grade 1) | 17.1 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypoglycemia (Grade 1) | 0 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypokalemia (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | ALT Increased (Grade 4) | 5.7 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hyponatremia (Grade 3) | 5.7 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Leukocytosis (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypoglycemia (Grade 2) | 0 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Blood Bilirubin Increased (Grade 3) | 2.9 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Chronic Kidney Disease (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Blood Bilirubin Increased (Grade 1) | 17.1 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Proteinuria (Grade 3) | 0 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Lymphocyte Count Decreased (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hyponatremia (Grade 2) | 0 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Proteinuria (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Chronic Kidney Disease (Grade 3) | 0 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Chronic Kidney Disease (Grade 2) | 0 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Proteinuria (Grade 1) | 22.9 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Leukocytosis (Grade 3) | 28.6 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypoglycemia (Grade 3) | 0 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Proteinuria (Grade 2) | 2.9 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | ALP Increased (Grade 2) | 2.9 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Chronic Kidney Disease (Grade 1) | 34.3 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypoalbuminemia (Grade 2) | 5.7 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypoalbuminemia (Grade 1) | 14.3 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Blood Bilirubin Increased (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Leukocytosis (Grade 2) | 0 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypoglycemia (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | AST Increased (Grade 4) | 5.7 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Platelets Count Decreased (Grade 3) | 5.7 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Lymphocyte Count Increased (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | AST Increased (Grade 3) | 0 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | ALT Increased (Grade 2) | 8.6 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Platelets Count Decreased (Grade 1) | 11.4 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | ALP Increased (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Lymphocyte Count Decreased (Grade 3) | 5.7 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | AST Increased (Grade 2) | 2.9 percentage of participants |
| Entospletinib + Idelalisib CLL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Platelets Count Decreased (Grade 2) | 2.9 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Aspartate Aminotransferase (AST)Increased(Grade 1) | 14.3 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Platelets Count Decreased (Grade 2) | 7.1 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Lymphocyte Count Increased (Grade 3) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | ALP Increased (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Platelets Count Decreased (Grade 3) | 14.3 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Lymphocyte Count Decreased (Grade 2) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | ALP Increased (Grade 3) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Platelets Count Decreased (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Proteinuria (Grade 2) | 14.3 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | ALP Increased (Grade 2) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Alanine Aminotransferase (ALT) Increased (Grade 1) | 7.1 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Alkaline Phosphatase (ALP) Increased (Grade 1) | 28.6 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | ALT Increased (Grade 2) | 7.1 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypoalbuminemia (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | ALT Increased (Grade 3) | 35.7 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Lymphocyte Count Decreased (Grade 1) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypoalbuminemia (Grade 3) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | ALT Increased (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypoalbuminemia (Grade 2) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypoalbuminemia (Grade 1) | 28.6 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Proteinuria (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Lymphocyte Count Increased (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | WBC Count Decreased (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Chronic Kidney Disease (Grade 2) | 7.1 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | WBC Count Decreased (Grade 3) | 14.3 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypokalemia (Grade 3) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | WBC Count Decreased (Grade 2) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | White Blood Cell Count Decreased (Grade 1) | 21.4 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hyperglycemia (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hyperglycemia (Grade 2) | 7.1 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Lymphocyte Count Increased (Grade 2) | 7.1 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Leukocytosis (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypoglycemia (Grade 2) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Leukocytosis (Grade 3) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypoglycemia (Grade 3) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hyponatremia (Grade 2) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Leukocytosis (Grade 2) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypoglycemia (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypoglycemia (Grade 1) | 14.3 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Leukocytosis (Grade 1) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hyponatremia (Grade 3) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Anemia (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypophosphatemia (Grade 3) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypophosphatemia (Grade 2) | 7.1 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Anemia (Grade 3) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Anemia (Grade 2) | 7.1 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypophosphatemia (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypokalemia (Grade 1) | 7.1 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Anemia (Grade 1) | 35.7 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypokalemia (Grade 2) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Lymphocyte Count Increased (Grade 1) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Neutrophils Count Decreased (Grade 4) | 7.1 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hyperglycemia (Grade 3) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Neutrophils Count Decreased (Grade 3) | 7.1 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hyponatremia (Grade 1) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Neutrophils Count Decreased (Grade 2) | 14.3 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypophosphatemia (Grade 1) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Neutrophils Count Decreased (Grade 1) | 21.4 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hyperglycemia (Grade 1) | 7.1 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypokalemia (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Lymphocyte Count Decreased (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Chronic Kidney Disease (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hyponatremia (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Blood Bilirubin Increased (Grade 1) | 14.3 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Chronic Kidney Disease (Grade 3) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Blood Bilirubin Increased (Grade 2) | 14.3 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Proteinuria (Grade 1) | 7.1 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Chronic Kidney Disease (Grade 1) | 42.9 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Lymphocyte Count Decreased (Grade 3) | 21.4 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | AST Increased (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Proteinuria (Grade 3) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Blood Bilirubin Increased (Grade 3) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Blood Bilirubin Increased (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | AST Increased (Grade 3) | 28.6 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | AST Increased (Grade 2) | 14.3 percentage of participants |
| Entospletinib + Idelalisib iNHL: FL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Platelets Count Decreased (Grade 1) | 28.6 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Anemia (Grade 1) | 16.7 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypophosphatemia (Grade 3) | 16.7 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hyponatremia (Grade 2) | 0 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hyponatremia (Grade 3) | 0 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Blood Bilirubin Increased (Grade 2) | 16.7 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Blood Bilirubin Increased (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Proteinuria (Grade 1) | 0 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Proteinuria (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hyperglycemia (Grade 3) | 0 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hyperglycemia (Grade 1) | 0 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hyperglycemia (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypoglycemia (Grade 1) | 0 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypoglycemia (Grade 2) | 0 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypoglycemia (Grade 3) | 0 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypoglycemia (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypophosphatemia (Grade 2) | 0 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypophosphatemia (Grade 1) | 0 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypophosphatemia (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypokalemia (Grade 1) | 33.3 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hyperglycemia (Grade 2) | 0 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypokalemia (Grade 2) | 0 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hyponatremia (Grade 1) | 50.0 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypokalemia (Grade 3) | 0 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypokalemia (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hyponatremia (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Blood Bilirubin Increased (Grade 1) | 50.0 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Proteinuria (Grade 2) | 0 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Proteinuria (Grade 3) | 0 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Blood Bilirubin Increased (Grade 3) | 0 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Lymphocyte Count Increased (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Platelets Count Decreased (Grade 1) | 16.7 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Platelets Count Decreased (Grade 2) | 0 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Platelets Count Decreased (Grade 3) | 0 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Platelets Count Decreased (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Alanine Aminotransferase (ALT) Increased (Grade 1) | 33.3 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | ALT Increased (Grade 2) | 0 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | ALT Increased (Grade 3) | 16.7 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | ALT Increased (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypoalbuminemia (Grade 1) | 0 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypoalbuminemia (Grade 2) | 16.7 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypoalbuminemia (Grade 3) | 16.7 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypoalbuminemia (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Alkaline Phosphatase (ALP) Increased (Grade 1) | 33.3 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | ALP Increased (Grade 2) | 0 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | ALP Increased (Grade 3) | 0 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | ALP Increased (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Aspartate Aminotransferase (AST)Increased(Grade 1) | 50.0 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | AST Increased (Grade 2) | 0 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | AST Increased (Grade 3) | 16.7 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | AST Increased (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Chronic Kidney Disease (Grade 1) | 50.0 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Chronic Kidney Disease (Grade 2) | 33.3 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Chronic Kidney Disease (Grade 3) | 0 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Chronic Kidney Disease (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Neutrophils Count Decreased (Grade 1) | 0 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Neutrophils Count Decreased (Grade 2) | 0 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Neutrophils Count Decreased (Grade 3) | 16.7 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Neutrophils Count Decreased (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Anemia (Grade 2) | 16.7 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Anemia (Grade 3) | 16.7 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Anemia (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Leukocytosis (Grade 1) | 0 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Leukocytosis (Grade 2) | 0 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Leukocytosis (Grade 3) | 0 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Leukocytosis (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | White Blood Cell Count Decreased (Grade 1) | 16.7 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | WBC Count Decreased (Grade 2) | 16.7 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | WBC Count Decreased (Grade 3) | 0 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | WBC Count Decreased (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Lymphocyte Count Decreased (Grade 1) | 0 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Lymphocyte Count Decreased (Grade 2) | 16.7 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Lymphocyte Count Decreased (Grade 3) | 50.0 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Lymphocyte Count Decreased (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Lymphocyte Count Increased (Grade 1) | 0 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Lymphocyte Count Increased (Grade 2) | 16.7 percentage of participants |
| Entospletinib + Idelalisib DLBCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Lymphocyte Count Increased (Grade 3) | 0 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Aspartate Aminotransferase (AST)Increased(Grade 1) | 0 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Platelets Count Decreased (Grade 1) | 33.3 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Lymphocyte Count Decreased (Grade 2) | 33.3 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | AST Increased (Grade 2) | 33.3 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Lymphocyte Count Increased (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | AST Increased (Grade 3) | 0 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Proteinuria (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | AST Increased (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Proteinuria (Grade 2) | 0 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Proteinuria (Grade 1) | 0 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Chronic Kidney Disease (Grade 1) | 33.3 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Blood Bilirubin Increased (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hyperglycemia (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Chronic Kidney Disease (Grade 2) | 0 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Blood Bilirubin Increased (Grade 2) | 0 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Blood Bilirubin Increased (Grade 1) | 0 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Lymphocyte Count Decreased (Grade 3) | 0 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hyponatremia (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hyponatremia (Grade 3) | 0 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Chronic Kidney Disease (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hyponatremia (Grade 2) | 0 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypokalemia (Grade 3) | 0 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Blood Bilirubin Increased (Grade 3) | 0 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Neutrophils Count Decreased (Grade 1) | 66.7 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hyponatremia (Grade 1) | 0 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Neutrophils Count Decreased (Grade 2) | 0 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypokalemia (Grade 2) | 0 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Lymphocyte Count Increased (Grade 3) | 0 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Neutrophils Count Decreased (Grade 3) | 0 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hyperglycemia (Grade 2) | 0 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Lymphocyte Count Decreased (Grade 4) | 33.3 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Neutrophils Count Decreased (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypokalemia (Grade 1) | 0 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Anemia (Grade 1) | 0 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypophosphatemia (Grade 3) | 0 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Anemia (Grade 2) | 0 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypokalemia (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Anemia (Grade 3) | 0 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypophosphatemia (Grade 2) | 0 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Anemia (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypoglycemia (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Leukocytosis (Grade 1) | 0 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypoglycemia (Grade 3) | 0 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Lymphocyte Count Increased (Grade 1) | 0 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Leukocytosis (Grade 2) | 0 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypoglycemia (Grade 2) | 0 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Leukocytosis (Grade 3) | 33.3 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypoglycemia (Grade 1) | 33.3 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Leukocytosis (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | White Blood Cell Count Decreased (Grade 1) | 0 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hyperglycemia (Grade 1) | 0 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypophosphatemia (Grade 1) | 0 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | WBC Count Decreased (Grade 2) | 33.3 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hyperglycemia (Grade 3) | 0 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Lymphocyte Count Increased (Grade 2) | 0 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | WBC Count Decreased (Grade 3) | 0 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Chronic Kidney Disease (Grade 3) | 0 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | ALP Increased (Grade 2) | 0 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | WBC Count Decreased (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypoalbuminemia (Grade 1) | 0 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | ALT Increased (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypoalbuminemia (Grade 2) | 33.3 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | ALT Increased (Grade 3) | 33.3 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypoalbuminemia (Grade 3) | 0 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypophosphatemia (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypoalbuminemia (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | ALT Increased (Grade 2) | 0 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Lymphocyte Count Decreased (Grade 1) | 0 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Alkaline Phosphatase (ALP) Increased (Grade 1) | 33.3 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Alanine Aminotransferase (ALT) Increased (Grade 1) | 0 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Platelets Count Decreased (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Proteinuria (Grade 3) | 0 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | ALP Increased (Grade 3) | 0 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Platelets Count Decreased (Grade 3) | 0 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | ALP Increased (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib MCL | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Platelets Count Decreased (Grade 2) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypoalbuminemia (Grade 1) | 12.5 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Aspartate Aminotransferase (AST)Increased(Grade 1) | 37.5 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Lymphocyte Count Increased (Grade 3) | 12.5 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Lymphocyte Count Increased (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | ALT Increased (Grade 4) | 12.5 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Leukocytosis (Grade 1) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | AST Increased (Grade 2) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypoglycemia (Grade 3) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Proteinuria (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Lymphocyte Count Decreased (Grade 2) | 12.5 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Platelets Count Decreased (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | AST Increased (Grade 3) | 12.5 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypoalbuminemia (Grade 3) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Proteinuria (Grade 2) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Blood Bilirubin Increased (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Lymphocyte Count Decreased (Grade 1) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | AST Increased (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Leukocytosis (Grade 2) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypoglycemia (Grade 2) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Blood Bilirubin Increased (Grade 3) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypoalbuminemia (Grade 2) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Chronic Kidney Disease (Grade 1) | 37.5 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Lymphocyte Count Increased (Grade 1) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | ALT Increased (Grade 3) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Leukocytosis (Grade 3) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Chronic Kidney Disease (Grade 2) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypoglycemia (Grade 1) | 25.0 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | ALP Increased (Grade 2) | 12.5 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hyponatremia (Grade 3) | 25.0 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Proteinuria (Grade 3) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Leukocytosis (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Lymphocyte Count Decreased (Grade 3) | 12.5 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hyperglycemia (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Chronic Kidney Disease (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hyponatremia (Grade 2) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hyperglycemia (Grade 3) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypokalemia (Grade 3) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Proteinuria (Grade 1) | 12.5 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | White Blood Cell Count Decreased (Grade 1) | 12.5 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Neutrophils Count Decreased (Grade 1) | 25.0 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hyponatremia (Grade 1) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hyperglycemia (Grade 1) | 12.5 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Blood Bilirubin Increased (Grade 2) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | ALT Increased (Grade 2) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Neutrophils Count Decreased (Grade 2) | 25.0 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypokalemia (Grade 2) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Platelets Count Decreased (Grade 3) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Platelets Count Decreased (Grade 1) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | WBC Count Decreased (Grade 2) | 12.5 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Neutrophils Count Decreased (Grade 3) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hyperglycemia (Grade 2) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypoalbuminemia (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Chronic Kidney Disease (Grade 3) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | ALP Increased (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Neutrophils Count Decreased (Grade 4) | 25.0 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypokalemia (Grade 1) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Alanine Aminotransferase (ALT) Increased (Grade 1) | 50.0 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypophosphatemia (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | WBC Count Decreased (Grade 3) | 12.5 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Anemia (Grade 1) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypophosphatemia (Grade 3) | 12.5 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | ALP Increased (Grade 3) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Lymphocyte Count Decreased (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypophosphatemia (Grade 1) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Anemia (Grade 2) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypokalemia (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Lymphocyte Count Increased (Grade 2) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Blood Bilirubin Increased (Grade 1) | 12.5 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Alkaline Phosphatase (ALP) Increased (Grade 1) | 12.5 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Anemia (Grade 3) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypophosphatemia (Grade 2) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | WBC Count Decreased (Grade 4) | 12.5 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hyponatremia (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Platelets Count Decreased (Grade 2) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Anemia (Grade 4) | 0 percentage of participants |
| Entospletinib + Idelalisib iNHL: Others | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Hypoglycemia (Grade 4) | 0 percentage of participants |
Secondary
Progression-free Survival (PFS)
PFS was defined as the interval from the first dose of study drug to the earlier of the first documentation of definitive disease progression or death from any cause.
Time frame: Start of treatment to end of treatment (Up to 18 months)
Population: The study was terminated due to safety measures. Complete data was not collected for any participant.
Secondary
Time to Response (TTR)
TTR was defined as the interval from the first dose of entospletinib/idelalisib to the time response (CR or PR \[or VGPR or MR for participants with LPL/WM\]) is first achieved. CR was defined as the complete resolution of all disease-related radiological abnormalities and the disappearance of all signs and symptoms related to the disease. PR was defined as a ≥ 50% reduction in the sum of the products of the longest perpendicular diameters of all index lesions, with no new lesions. VGPR and MR were defined as ≥ 90% and ≥ 25% but \< 50% decrease from baseline in serum monoclonal IgM concentration by SPEP respectively.
Time frame: Start of treatment to end of treatment (Up to 18 months)
Population: The study was terminated due to safety measures. Complete data was not collected for any participant.